CAS 147098-18-8|Rosuvastatin calcium
Introduction：Basic information about CAS 147098-18-8|Rosuvastatin calcium, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Rosuvastatin calcium | ||
|---|---|---|---|
| CAS Number | 147098-18-8 | Molecular Weight | 503.520 |
| Density | / | Boiling Point | / |
| Molecular Formula | C22H27FN3NaO6S | Melting Point | 128-131℃ |
| MSDS | / | Flash Point | / |
Names
| Name | sodium,7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate |
|---|---|
| Synonym | More Synonyms |
Rosuvastatin calcium BiologicalActivity
| Description | Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM[2]. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>HMG-CoA Reductase (HMGCR)Signaling Pathways >>Autophagy >>AutophagyResearch Areas >>Metabolic DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>Potassium Channel |
| Target | IC50: 11 nM (HMG-CoA), 195 nM (hERG)[1][2] |
| In Vivo | Rosuvastatin Sodium (10 mg/kg, intraperitoneal) prolonges QTc in conscious and unrestraines guinea pigs from 201±1 to 210±2 ms[2]. Rosuvastatin (20 mg/kg/day, for 2 weeks) significantly reduces very low-density lipoproteins Sodium (VLDL) in diabetes mellitus rats induced by Streptozocin[4]. |
| References | [1]. Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44. [2]. Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101(2):868-78. [3]. Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16(4):1477-1488. [4]. Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7. |
Chemical & Physical Properties
| Melting Point | 128-131℃ |
|---|---|
| Molecular Formula | C22H27FN3NaO6S |
| Molecular Weight | 503.520 |
| Exact Mass | 503.150238 |
| PSA | 152.13000 |
| LogP | 2.14780 |
| InChIKey | RGEBGDYYHAFODH-DHMAKVBVSA-M |
| SMILES | CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=CC(O)CC(O)CC(=O)[O-].[Na+] |
Safety Information
| Hazard Codes | Xi |
|---|
Synonyms
| Sodium (6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl}-3,5-dihydroxy-6-heptenoate |
| Rosuvastatin Sodium |
| 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt, (6E)- (1:1) |
